

FOCUS EDITORIAL



Focus on ARDS

Ary Serpa Neto^{1,2}, Armand Mekontso Dessap^{3,4} and Laurent Papazian^{5*}

© 2017 Springer-Verlag GmbH Germany and ESICM

Since 1967, when first described, ARDS has been widely recognized as a major health problem worldwide, carrying a high morbidity and mortality [1–3]. This focus editorial summarizes recent advances about the incidence, pathophysiology, right ventricular dysfunction, and mortality of ARDS.

Despite the attempt to homogenize its definition following the publication of the Berlin criteria, there is still a high heterogeneity in the epidemiology of ARDS across the world [3]. Indeed, estimates of the incidence of ARDS are highly variable, ranging from less than 2 to more than 70 cases per 100,000 person-years, with the most recent study on the topic suggesting a higher incidence in Europe, North America, and Oceania compared to South America, Asia, and Africa [2, 3]. However, it is important to emphasize that this scenario could only reflect the under-recognition of this syndrome [3]. Recent reports suggest a progressive decline of the incidence of ARDS. In a study conducted in Rochester, cases fell by half between 2001 and 2008 while mortality remained stable [4]. Nearly all of the reduction in the incidence was observed in hospital-acquired ARDS, suggesting that ARDS could be prevented through strategies addressing its related risk factors [4, 5]. However, in some instances, patients meeting the Berlin criteria for ARDS lack exposure to common risk factors [6]. It was recently reported that the prevalence of patients with ARDS but without common risk factors was as high as 7.5% [6]. According to medical history, bronchoalveolar lavage fluid cytology, and chest computed tomography (CT) scan patterns, four etiological categories were identified in this group of patients: immune, drug-induced, malignant, and idiopathic [6]. The overall ICU mortality rate was higher in patients lacking common risk factors as compared to

their counterparts, even after adjustment for potential confounding factors [6].

It is already well known that ventilator-induced lung injury contributes to ARDS-associated mortality [2, 3]. Recently, some biological markers have been proposed as potential biomarkers of ARDS, such as the soluble form of the receptor for advanced glycation end-products (sRAGE). This biomarker is a transmembrane receptor that can bind multiple ligands resulting in intracellular signaling, leading to activation of the proinflammatory transcription factor nuclear factor κ B [7]. Plasma levels of sRAGE could change according to ventilator settings in ARDS patients, as recently suggested by a study describing a significant decrease of sRAGE 1 h after a recruitment maneuver followed by an increase toward baseline values 4 h after the maneuver [7]. It has also been shown that sRAGE is higher in non-survivors than survivors in early pediatric ARDS and strongly correlated with number of non-pulmonary organ failures [8]. Other biomarkers of endothelial injury are also investigated in ARDS patients. Higher levels of circulating endothelial cells were found in the blood of patients with moderate-to-severe ARDS as compared to those with mild or without ARDS [9]. Soluble thrombomodulin (sTM) is another biomarker of endothelial injury investigated in ARDS patients [10]. A recent post hoc analysis of a huge cohort showed that higher plasma levels of sTM are associated with increased mortality in ARDS patients [10]. Also, the lack of association between the sTM levels and genetic variants reported in this latter study suggests that the increased levels of sTM may reflect severity of endothelial damage rather than genetic heterogeneity [10]. Finally, the prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) was recently assessed in a series of 632 ARDS patients, and increased levels of plasma suPAR were significantly associated with ICU mortality [11]. Altogether, these promising endothelial biomarkers may guide the development of future strategies targeting endothelial stabilization,

*Correspondence: laurent.papazian@ap-hm.fr

⁵ Réanimation des Détresses Respiratoires et Infections Sévères, Assistance Publique - Hôpitaux de Marseille, Hôpital Nord, Aix-Marseille Université, Faculté de Médecine, 13015 Marseille, France
Full author information is available at the end of the article

repair, and/or functional replacement in certain ARDS categories. However, their prominent involvement during indirect lung injury likely reflects increased inflammation and both pulmonary and systemic endothelial damage. Indeed, the severity of pulmonary vascular injury is quite disparate between ARDS patients and may prevail during indirect injury.

Right ventricular dysfunction may reflect the presence of lung vascular dysfunction during ARDS. In a series of more than 750 patients, the prevalence of acute cor pulmonale during ARDS was found to be 22%, with severe forms being associated with increased mortality [12]. A simple clinical risk score of acute cor pulmonale was proposed, including four variables: pneumonia as a cause of ARDS, driving pressure at least 18 cmH₂O, PaO₂/FiO₂ ratio less than 150 mmHg, and arterial PaCO₂ at least 48 mmHg [12]. This score may help in selecting patients to be monitored for early identification of acute cor pulmonale, preferably with transesophageal echocardiography [12]. Indeed, recent studies and reviews have reinforced the seminal role of ultrasound in general, and transesophageal echocardiography in particular, in the diagnostic workup and monitoring of ARDS patients [13]. The direct assessment of pulmonary vascular dysfunction at the bedside is still a clinical challenge, but emerging techniques like electric impedance tomography may provide informative data on regional distribution of lung perfusion in the near future [14].

The majority of the patients diagnosed with ARDS present it in its moderate form, with an in-hospital mortality rate around 40% [3]. There is a high variability in reported mortality of ARDS patients, probably reflecting differences in care, risk factors, ability to diagnose, and resource availability. However, in general, recent studies suggest a decrease in mortality rate from ARDS probably due to better ventilatory care and control of modifiable risk factors associated with mortality [15].

While we are interested in developing new concepts or techniques to improve mechanical ventilation care or associated measures, we should have in mind that this type of support cannot cure the patient if the cause of ARDS is not promptly identified and the resulting treatment quickly initiated. This is particularly the case in ARDS related to a direct lung injury which needs a systematic approach based on bronchoalveolar lavage and blood samples to identify the cause of ARDS and to guide the correct treatment [13].

For more information regarding ARDS, there is a recent series of up-to-date review articles published in *Intensive Care Medicine* for the 50th birthday of the first description of ARDS.

Author details

¹ Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil. ² Department of Intensive Care, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. ³ Service de Réanimation Médicale, Assistance Publique - Hôpitaux de Paris, Hôpital Henri Mondor, DHU A-TV8, 94010 Créteil, France. ⁴ Groupe de Recherche Clinique CARMAS, Faculté de Médecine, IMRB, Université Paris Est Créteil, 94010 Créteil, France. ⁵ Réanimation des Détresses Respiratoires et Infections Sévères, Assistance Publique - Hôpitaux de Marseille, Hôpital Nord, Aix-Marseille Université, Faculté de Médecine, 13015 Marseille, France.

Compliance with ethical standards

Conflicts of interest

Ary Serpa Neto, Armand Mekontso Dessap, and Laurent Papazian do not have any conflict of interest to declare regarding this manuscript.

Received: 29 June 2017 Accepted: 28 July 2017

Published online: 04 August 2017

References

1. Beitler JR, Goligher EC, Schmidt M, Spieth PM, Zanella A, Martin-Loeches I, Calfee CS, Cavalcanti AB, ARDSne(x)t Investigators (2016) Personalized medicine for ARDS: the 2035 research agenda. *Intensive Care Med* 42:756–767
2. Villar J, Blanco J, Anón JM, Santos-Bouza A, Blanch L, Ambrós A, Gandía F, Carriedo D, Mosteiro F, Basaldúa S, Fernández RL, Kacmarek RM, ALIEN Network (2011) The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. *Intensive Care Med* 37:1932–1941
3. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A, LUNG SAFE Investigators, ESICM Trials Group (2016) Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. *JAMA* 315:788–800
4. Li G, Malinchoc M, Cartin-Ceba R, Venkata CV, Kor DJ, Peters SG, Hubmayr RD, Gajic O (2011) Eight-year trend of acute respiratory distress syndrome: a population-based study in Olmsted County, Minnesota. *Am J Respir Crit Care Med* 183:59–66
5. Neto AS, Jaber S (2016) What's new in mechanical ventilation in patients without ARDS: lessons from the ARDS literature. *Intensive Care Med* 42:787–789
6. Gibelin A, Parrot A, Maitre B, Brun-Buisson C, Mekontso Dessap A, Fartoukh M, de Prost N (2016) Acute respiratory distress syndrome mimickers lacking common risk factors of the Berlin definition. *Intensive Care Med* 42:164–172
7. Jabaudon M, Hamroun N, Roszyk L, Guérin R, Bazin JE, Sapin V, Pereira B, Constantin JM (2015) Effects of a recruitment maneuver on plasma levels of soluble RAGE in patients with diffuse acute respiratory distress syndrome: a prospective randomized crossover study. *Intensive Care Med* 41:846–855
8. Yehya N, Thomas NJ, Meyer NJ, Christie JD, Berg RA, Margulies SS (2016) Circulating markers of endothelial and alveolar epithelial dysfunction are associated with mortality in pediatric acute respiratory distress syndrome. *Intensive Care Med* 42:1137–1145
9. Moussa MD, Santonocito C, Fagnoul D, Donadello K, Pradier O, Gaussem P, De Backer D, Vincent JL (2015) Evaluation of endothelial damage in sepsis-related ARDS using circulating endothelial cells. *Intensive Care Med* 41:231–238
10. Sapru A, Calfee CS, Liu KD, Kangelaris K, Hansen H, Pawlikowska L, Ware LB, Alkhouli MF, Abbott J, Matthay MA, NHLBI ARDS Network (2015) Plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome. *Intensive Care Med* 41:470–478
11. Geboers DG, de Beer FM, Tuip-de Boer AM, van der Poll T, Horn J, Cremer OL, Bonten MJ, Ong DS, Schultz MJ, Bos LD (2015) Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients. *Intensive Care Med* 41:1281–1290

-
12. Mekontso Dessap A, Boissier F, Charron C, Bégot E, Repessé X, Legras A, Brun-Buisson C, Vignon P, Vieillard-Baron A (2016) Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact. *Intensive Care Med* 42:862–870
 13. Papazian L, Calfee CS, Chiumello D, Luyt CE, Meyer NJ, Sekiguchi H, Matthay MA, Meduri GU (2016) Diagnostic workup for ARDS patients. *Intensive Care Med* 42:674–685
 14. Mauri T, Eronia N, Turrini C, Battistini M, Grasselli G, Rona R, Volta CA, Bellani G, Pesenti A (2016) Bedside assessment of the effects of positive end-expiratory pressure on lung inflation and recruitment by the helium dilution technique and electrical impedance tomography. *Intensive Care Med* 42:1576–1587
 15. Laffey JG, Bellani G, Pham T, Fan E, Madotto F, Bajwa EK, Brochard L, Clarkson K, Esteban A, Gattinoni L, van Haren F, Heunks LM, Kurahashi K, Laake JH, Larsson A, McAuley DF, McNamee L, Nin N, Qiu H, Ranieri M, Rubenfeld GD, Thompson BT, Wrigge H, Slutsky AS, Pesenti A, LUNG SAFE Investigators and the ESICM Trials Group (2016) Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study. *Intensive Care Med* 42:1865–1876